

Allergy Therapeutics^{PLC}

Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Company to Evaluate Dual Listing on HKEX

Worthing, UK - 6 November 2025: Allergy Therapeutics plc, the fully integrated commercial biotechnology company specialising in allergy immunotherapies, announces that it is exploring a dual primary listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX").

This potential listing in Hong Kong, alongside the Company's existing listing on the London Stock Exchange's AIM market, reflects Allergy Therapeutics' desire to expand its presence in Asia and become a global leader in allergy treatments, while also enhancing trading liquidity in its ordinary shares. The Board believes that an HKEX listing and an associated equity offering would broaden the Company's investor base to include Hong Kong and mainland Chinese investors, aligning with the Company's growth ambitions in the region.

Preparatory work to explore the possible dual listing is underway, and if the Company decides to proceed with these plans, it would be targeting the HKEX listing becoming effective during the course of the first half of 2026, depending on market conditions. An application for listing of the Company's shares on HKEX would be subject to review and approval by the HKEX and the Securities and Futures Commission of Hong Kong, and there is no guarantee that the Company will proceed with such listing application.

Manuel Llobet, CEO of Allergy Therapeutics, commented: *"We believe that a dual listing in Hong Kong could be an important step forwards for the Company. This initiative aligns well with our Asia expansion strategy and our aim to become a truly global player in the allergy immunotherapy field. By establishing a presence on HKEX, we would be able to engage more directly with Asian investors and support our growth in Asian markets, which we see as a key driver for Allergy Therapeutics' future success."*

Allergy Therapeutics will make further announcements as appropriate to keep the market informed of material developments.

Regulatory Notices:

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014) which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain. The person responsible for arranging for the release of this announcement on behalf of the Company is Shaun Furlong, Chief Financial Officer.

This announcement is being issued for information purposes only and does not constitute an offer to sell or issue, or the solicitation of an offer to buy, any securities of the Company in any jurisdiction. In particular, no securities of the Company have been or will be registered under the U.S. Securities Act of 1933, and no public offering is being made in the United States.

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/Seamus Fricker
Nigel Birks - Life Science Specialist Sales
+44 (0)20 7220 0500

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFBFBRTMTTMMMA